Biogen Targets Rare Diseases, Eyes $800M Cost Cuts With 'Fit for Growth' Plan

Biogen Inc. (NASDAQ:BIIB) is one of the 15 best stocks to invest in for an 18 year old. On June 10, Biogen Inc. (NASDAQ:BIIB) gave a presentation at the Goldman Sachs 46th Annual Global Healthcare Conference 2025, highlighting its strategic planning and current challenges. The company’s investments in new product releases and its advancements into immunology and nephrology were emphasized by CFO Robin Kramer.

Notably, Biogen Inc. (NASDAQ:BIIB) anticipates that its Fit for Growth program will result in net cost reductions of $800 million by the end of the year. The company is currently focusing on nine initiatives that are focused on rare diseases and neurology and are in Phase 3 or Phase 3-ready phases. Additionally, Biogen announced that it has expanded into kidney disease and nephrology, adding three new indications, with the help of its West Coast headquarters.

Moreover, according to the firm’s management, Biogen’s upcoming Rare Disease Day will focus on primarily on rare and kidney disorders as well as assets the company acquired through the Hibio acquisition.

Biogen Inc. (NASDAQ:BIIB) is a multinational biopharmaceutical company dedicated to discovering, developing, and providing innovative treatments to patients with severe complex illnesses.

While we acknowledge the potential of BIIB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.